Seminars in Oncology
Volume 33 , Pages 44-52 , April 2006

The Role of Alemtuzumab in the Management of T-Cell Malignancies

  • Claire Dearden

      Affiliations

    • Dr Dearden has served as a consultant and speaker for Berlex Oncology and Schering AG.
    • Corresponding Author InformationAddress reprint requests to Claire Dearden, MD, Department of Haemato-oncology, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom.

References 

  1. Goldrath AW , Bevan MJ . Selecting and maintaining a diverse T-cell repertoire . Nature . 1999;402:255–262
  2. Bommhardt U , Beyer M , Hunig T , et al.   Molecular and cellular mechanisms of T cell development . Cell Mol Life Sci . 2004;61:263–280
  3. Jaffe ES , Krenacs L , Raffeld M . Classification of cytotoxic T-cell and natural killer cell lymphomas . Semin Hematol . 2003;40:175–184
  4. Brito-Babapulle V , Catovsky D . Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia . Cancer Genet Cytogenet . 1991;55:1–9
  5. Matutes E , Brito-Babapulle V , Swansbury J , et al.   Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia . Blood . 1991;78:3269–3274
  6. Ginaldi L , De Martinis M , Matutes E , et al.   Levels of expression of CD52 in normal and leukemic B and T cells (correlation with in vivo therapeutic responses to Campath-1H) . Leuk Res . 1998;22:185–191
  7. Sugimoto T , Imoto S , Matsuo Y , et al.   T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype . Ann Hematol . 2001;80:749–751
  8. Stilgenbauer S , Schaffner C , Litterst A , et al.   Biallelic mutations in the ATM gene in T-prolymphocytic leukemia . Nat Med . 1997;3:1155–1159
  9. Stoppa-Lyonnet D , Soulier J , Lauge A , et al.   Inactivation of the ATM gene in T-cell prolymphocytic leukemias . Blood . 1998;91:3920–3926
  10. Yuille MA , Coignet LJ . The ataxia telangiectasia gene in familial and sporadic cancer . Recent Results Cancer Res . 1998;154:156–173
  11. Yamaguchi M , Yamamoto K , Miki T , et al.   T-cell prolymphocytic leukemia with der(11)t(1;11)(q21;q23) and ATM deficiency . Cancer Genet Cytogenet . 2003;146:22–26
  12. Virgilio L , Narducci MG , Isobe M , et al.   Identification of the TCL1 gene involved in T-cell malignancies . Proc Natl Acad Sci U S A . 1994;91:12530–12534
  13. Madani A , Choukroun V , Soulier J , et al.   Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations . Blood . 1996;87:1923–1927
  14. Laine J , Kunstle G , Obata T , et al.   The protooncogene TCL1 is an Akt kinase coactivator . Mol Cell . 2000;6:395–407
  15. Herling M , Khoury JD , Washington LT , et al.   A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories . Blood . 2004;104:328–335
  16. Soulier J , Pierron G , Vecchione D , et al.   A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia . Genes Chromosomes Cancer . 2001;31:248–254
  17. Kojima K , Kobayashi H , Imoto S , et al.   14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia . Int J Hematol . 1998;68:291–296
  18. Mercieca J , Matutes E , Dearden C , et al.   The role of pentostatin in the treatment of T-cell malignancies (analysis of response rate in 145 patients according to disease subtype) . J Clin Oncol . 1994;12:2588–2593
  19. Delgado J , Bustos JG , Jimenez MC , et al.   Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders? . Leuk Lymphoma . 2002;43:2331–2334
  20. Pawson R , Dyer MJ , Barge R , et al.   Treatment of T-cell prolymphocytic leukemia with human CD52 antibody . J Clin Oncol . 1997;15:2667–2672
  21. Dearden CE , Matutes E , Cazin B , et al.   High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H . Blood . 2001;98:1721–1726
  22. Keating MJ , Cazin B , Coutre S , et al.   Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed . J Clin Oncol . 2002;20:205–213
  23. Dearden C , Matutes E , Cazin B , et al.   Very high response rates in previously untreated T-cell Prolymphocytic leukaemia patients receiving alemtuzumab (Campath-1H) therapy . Blood . 2003;102:2378; (abstr 2378)
  24. Hopfinger G , Kandler G , Koller E , et al.   T-PLL-1 Protocol of the German CLL Study Group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation as first line treatment in T-PLL . Blood . 2003;102:2495; (abstr)
  25. Krishnan B , Swansbury J , Cazin B , et al.   Clinical outcome of stem cell transplantation (SCT) in patients with T cell prolymphocytic leukaemia (T-PLL) previously treated with alemtuzumab (A multicentre experience) . 2005; Abstract presented at the American Society of Hematology, December 10, Atlanta, GA (abstr 2541)
  26. Absi A , His E , Kalaycio M . Prolymphocytic leukemia . Curr Treat Options Oncol . 2005;6:197–208
  27. Lamy T , Loughran TP . Current concepts (Large granular lymphocyte leukemia) . Blood Rev . 1999;13:230–240
  28. Dang NH , Aytac U , Sato K , et al.   T-large granular lymphocyte lymphoproliferative disorder (Expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition) . Br J Haematol . 2003;121:857–865
  29. Tsang WY , Chan JK , Yip TT , et al.   In situ localization of Epstein-Barr virus encoded RNA in non-nasal/nasopharyngeal CD56-positive and CD56-negative T-cell lymphomas . Hum Pathol . 1994;25:758–765
  30. Wong KF , Chan JC , Liu HS , et al.   Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia (Report of two cases and review of the literature) . Br J Haematol . 2002;116:598–600
  31. Man C , Au WY , Pang A , et al.   Deletion 6q as a recurrent chromosomal aberration in T-cell large granular lymphocyte leukemia . Cancer Genet Cytogenet . 2002;139:71–74
  32. Skacel M , Maciejewski J , Kandil D , et al.   Recurrent genomic imbalances in T-cell large granular lymphocytes (T-LGL) leukemia detected by array-based comparative genomic hybridization (CGH) . Blood . 2003;102:4768; (abstr)
  33. Bigouret V , Hoffmann T , Arlettaz L , et al.   Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors . Blood . 2003;101:3198–3204
  34. Siu LL , Wong KF , Chan JK , et al.   Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations . Am J Pathol . 1999;155:1419–1425
  35. Saunthararajah Y , Molldrem JL , Rivera M , et al.   Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease (Clinical and pathophysiological features) . Br J Haematol . 2001;112:195–200
  36. Loughran TP , Kidd PG , Starkebaum G . Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate . Blood . 1994;84:2164–2170
  37. Osuji N , Del Giudice I , Matutes E , et al.   Treatment of T-cell large granular lymphocytic leukaemia (The role for methotrexate and cyclosporin A in new, relapsed and refractory cases) . Blood . 2003;102:1467; (abstr)
  38. Sternberg A , Eagleton H , Pillai N , et al.   Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity . Br J Haematol . 2003;120:699–701
  39. Ru X , Liebman HA . Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) . Br J Haematol . 2003;123:278–281
  40. Rosenblum MD , LaBelle JL , Chang CC , et al.   Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia . Blood . 2004;103:1969–1971
  41. Bekkenk MW , Jansen PM , Meijer CJ , et al.   CD56+ hematological neoplasms presenting in the skin (A retrospective analysis of 23 new cases and 130 cases from the literature) . Ann Oncol . 2004;15:1097–1108
  42. Shapiro M , Wasik MA , Junkins-Hopkins JM , et al.   Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen . Am J Hematol . 2003;74:46–51
  43. Ebihara Y , Manabe A , Tanaka R , et al.   Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation . Bone Marrow Transplant . 2003;31:1169–1171
  44. Hyakuna N , Toguchi S , Higa T , et al.   Childhood blastic NK cell leukemia successfully treated with L-asparagenase and allogeneic bone marrow transplantation . Pediatr Blood Cancer . 2004;42:631–634
  45. Okamura T , Kishimoto T , Inoue M , et al.   Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease . Bone Marrow Transplant . 2003;31:105–111
  46. Mahieux R , Gessain A . HTLV-1 and associated adult T-cell leukemia/lymphoma . Rev Clin Exp Hematol . 2003;7:336–361
  47. Gotoh YI , Sugamura K , Hinuma Y . Healthy carriers of a human retrovirus, adult T-cell leukemia virus (ATLV) (Demonstration by clonal culture of ATLV-carrying T cells from peripheral blood) . Proc Natl Acad Sci U S A . 1982;79:4780–4782
  48. Portis T , Harding JC , Ratner L . The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors . Blood . 2001;98:1200–1208
  49. Iwanaga R , Ohtani K , Hayashi T , et al.   Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I . Oncogene . 2001;20:2055–2067
  50. Kohno T , Moriuchi R , Katamine S , et al.   Identification of genes associated with the progression of adult T cell leukemia (ATL) . Jpn J Cancer Res . 2000;91:1103–1110
  51. Arima N , Tei C . HTLV-I Tax related dysfunction of cell cycle regulators and oncogenesis of adult T cell leukemia . Leuk Lymphoma . 2001;40:267–278
  52. Kamada N , Sakurai M , Miyamoto K , et al.   Chromosome abnormalities in adult T-cell leukemia/lymphoma (A karyotype review committee report) . Cancer Res . 1992;52:1481–1493
  53. Seiki M , Eddy R , Shows TB , et al.   Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells . Nature . 1984;309:640–642
  54. Yamada Y , Tomonaga M , Fukuda H , et al.   A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma (Japan Clinical Oncology Group Study 9303) . Br J Haematol . 2001;113:375–382
  55. Matutes E , Taylor GP , Cavenagh J , et al.   Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma (Response and outcome in 15 patients) . Br J Haematol . 2001;113:779–784
  56. White JD , Wharfe G , Stewart DM , et al.   The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma . Leuk Lymphoma . 2001;40:287–294
  57. Hermine O , Allard I , Levy V , et al.   A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma . Hematol J . 2002;3:276–282
  58. Hermine O , Dombret H , Poupon J , et al.   Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma . Hematol J . 2004;5:130–134
  59. Ishida T , Lida S , Akatsua Y , et al.   CCR4 (Chemokine receptor as a novel molecular target for immunotherapy in adult T-cell leukemia/lymphoma (ATLL)) . Blood . 2003;102:3348; (abstr 3348)
  60. Zhang Z , Zhang M , Goldman CK , et al.   Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H . Cancer Res . 2003;63:6453–6457
  61. Taylor PG , Matsuoka M . Natural history of adult T-cell leukemia/lymphoma and approaches to therapy . Oncogene . 2005;24:6047–6057
  62. Porcu P , Mone A , Puhalla S , et al.   Durable complete response of the human T-cell leukemia virus (HTLV-1) viral load (VL) with alemtuzumab in refractory adult T-cell leukemia (ATL) . J Clin Oncol . 2005;28:6639; (abstr)
  63. Whittam LR , Calonje E , Orchard G , et al.   CD8-positive juvenile onset mycosis fungoides (An immunohistochemical and genotypic analysis of six cases) . Br J Dermatol . 2000;143:1199–1204
  64. Scarisbrick JJ , Woolford AJ , Russell-Jones R , et al.   Allelotyping in mycosis fungoides and Sezary syndrome (Common regions of allelic loss identified on 9p, 10q, and 17p) . J Invest Dermatol . 2001;117:663–670
  65. Herrmann JJ , Roenigk HH , Hurria A , et al.   Treatment of mycosis fungoides with photochemotherapy (PUVA) (Long-term follow-up) . J Am Acad Dermatol . 1995;33:234–242
  66. McGinnis KS , Junkins-Hopkins JM , Crawford G , et al.   Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma (Clinical synergism and possible immunologic mechanisms) . J Am Acad Dermatol . 2004;50:375–379
  67. Kuzel TM , Roenigk HH , Samuelson E , et al.   Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome . J Clin Oncol . 1995;13:257–263
  68. Rupoli S , Barulli S , Guiducci B , et al.  Cutaneous-T Cell Lymphoma Multicenter Study Group   Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides (Results of a multicenter study) . Haematologica . 1999;84:809–813
  69. Chiarion-Sileni V , Bononi A , Fornasa CV , et al.   Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma . Cancer . 2002;95:569–575
  70. Duvic M , Hymes K , Heald P , et al.   Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma (Multinational phase II-III trial results) . J Clin Oncol . 2001;19:2456–2471
  71. Wollina U , Dummer R , Brockmeyer NH , et al.   Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma . Cancer . 2003;98:993–1001
  72. Scarisbrick JJ , Child FJ , Clift A , et al.   A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma . Br J Dermatol . 2001;144:1010–1015
  73. Dearden C , Matutes E , Catovsky D . Pentostatin treatment of cutaneous T-cell lymphoma . Oncology (Huntingt) . 2000;14:37–40
  74. Kuzel TM , Hurria A , Samuelson E , et al.   Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma . Blood . 1996;87:906–911
  75. Kong LR , Samuelson E , Rosen ST , et al.   2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders . Leuk Lymphoma . 1997;26:89–97
  76. Foss FM , Ihde DC , Linnoila IR , et al.   Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome . J Clin Oncol . 1994;12:2051–2059
  77. Saleh MN , LeMaistre CF , Kuzel TM , et al.   Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides . J Am Acad Dermatol . 1998;39:63–73
  78. Olsen E , Duvic M , Frankel A , et al.   Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma . J Clin Oncol . 2001;19:376–388
  79. Obitz E , Kim YH , Iversen L , et al.   HuMax-CD4, a fully human monoclonal antibody (early results of an ongoing phase II trial in cutaneous T cell lymphoma (CTCL)) . Blood . 2003;102:2383; (abstr)
  80. Lundin J , Osterborg A , Brittinger G , et al.  European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma   CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas (A phase II multicenter study) . J Clin Oncol . 1998;16:3257–3263
  81. Kennedy GA , Seymour JF , Wolf M , et al.   Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab . Eur J Haematol . 2003;71:250–256
  82. Foukaneli T , Marsh J , Pettegell R , et al.   Sezary syndrome responds to treatment with Campath-1H . Blood . 2001;98:556; (abstr)
  83. Capalbo S , Delia M , Dargenio M , et al.   Mycosis fungoides/Sezary syndrome (A report of three cases treated with Campath-1H as salvage treatment) . Med Oncol . 2003;20:389–396
  84. Lenihan DJ , Alencar AJ , Yang D , et al.   Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome . Blood . 2004;104:655–658
  85. Lundin J , Kennedy B , Dearden C , et al.   Correspondence (No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome) . Blood . 2005;105:4148–4149
  86. Weder P , Anliker M , Itin P , et al.   Familial cutaneous mycosis fungoides (Successful treatment with a combination of gemcitabine and alemtuzumab) . Dermatology . 2004;208:281–283
  87. Barry TS , Jaffe ES , Sorbara L , et al.   Peripheral T-cell lymphomas expressing CD30 and CD15 . Am J Surg Pathol . 2003;27:1513–1522
  88. Ruco LP , Di Napoli A , Pilozzi E , et al.   Peripheral T cell lymphoma with cytotoxic phenotype (An emerging disease in HIV-infected patients?) . AIDS Res Hum Retroviruses . 2004;20:129–133
  89. Zettl A , Rudiger T , Konrad MA , et al.   Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations . Am J Pathol . 2004;164:1837–1848
  90. Mori A , Takao S , Pradutkanchana J , et al.   High tumor necrosis factor-alpha levels in the patients with Epstein-Barr virus-associated peripheral T-cell proliferative disease/lymphoma . Leuk Res . 2003;27:493–498
  91. Dutcher JP . The role of Epstein-Barr virus and elevated levels of tumor necrosis factor in determining prognosis in Asian peripheral T-cell lymphomas . Leuk Res . 2003;27:467–469
  92. Rassidakis GZ , Jones D , Lai R , et al.   BCL-2 family proteins in peripheral T-cell lymphomas (Correlation with tumour apoptosis and proliferation) . J Pathol . 2003;200:240–248
  93. Jöhrens K . ALK-negative anaplastic large cell lymphomas represent a distinct entity . Ann Oncol . 2005;16:512; (abstr)
  94. Pellatt J , Sweetenham J , Pickering RM , et al.   A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin’s lymphoma . Ann Hematol . 2002;81:267–272
  95. Musson R , Radstone CR , Horsman JM , et al.   Peripheral T cell lymphoma (The Sheffield Lymphoma Group experience (1977-2001)) . Int J Oncol . 2003;22:1363–1368
  96. Lee HK , Wilder RB , Jones D , et al.   Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas . Leuk Lymphoma . 2002;43:1769–1775
  97. Weidmann E , Hess G , Krause SW , et al.   Combination chemoimmunotherapy using alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin is an effective first-line regimen in peripheral T-cell lymphomas . Blood . 2004;104:2640; (abstr)
  98. Gallamini A , Zaja F , Gargantini L , et al.   CHOP chemotherapy plus Campath-1H (CHOP-C) as first line treatment in patients with peripheral T-cell lymphoma (PTCL) . Ann Oncol . 2005;16:321; (abstr)
  99. Tsimberidou AM , Giles F , Duvic M , et al.   Phase II study of pentostatin in advanced T-cell lymphoid malignancies (Update of an M.D. Anderson Cancer Center series) . Cancer . 2004;100:342–349
  100. Enblad G , Hagberg H , Eriksson M , et al.   A pilot study of alemtuzumab (Anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphoma . Blood . 2003;102:2384; (abstr)
  101. Rodriguez J , Caballero MD , Gutierrez A , et al.   High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience . Haematologica . 2003;88:1372–1377
  102. Rodriguez J , Caballero MD , Gutierrez A , et al.   Long-term follow-up of autologous stem cell transplantation (ASCT) in patients with peripheral T-cell lymphoma (PTCL) (The Spanish Lymphoma Cooperative Group (GEL-TAMO) experience) . Ann Oncol . 2005;16:72; (abstr)
  103. Kahl C , Leithauser M , Wolff D , et al.   Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation . Ann Hematol . 2002;81:646–650

PII: S0093-7754(06)00061-3

doi: 10.1053/j.seminoncol.2006.01.029

Seminars in Oncology
Volume 33 , Pages 44-52 , April 2006

Article Tools

* Image Usage & Resolution